Finoriq research workspace
Camp4 Therapeutics Corp (CAMP) Company Overview
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops. Review CAMP filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Company
- Camp4 Therapeutics Corp (CAMP)
- Ticker
- CAMP
- Market Cap
- $173.2M
- Latest Price
- $3.335
- Industry
- Unclassified
Camp4 Therapeutics Corp (CAMP) Current Valuation Metrics
Static valuation preview for Camp4 Therapeutics Corp (CAMP). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 57.9x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -37.9% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -11.5% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 7.38x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.